Cadrenal Therapeutics Inc (CVKD)

Feb 06, 2025

Cadrenal Therapeutics appoints new chief medical officer - MSN

Feb 06, 2025

Feb 06, 2025

Clinical Trials News Live Feed - StockTitan

Feb 06, 2025

Feb 06, 2025

Cadrenal Therapeutics appoints new chief medical officer By Investing.com - Investing.com UK

Feb 06, 2025

Feb 06, 2025

Former Amgen & AstraZeneca Executive Takes Helm of Revolutionary Anticoagulation Drug Development - StockTitan

Feb 06, 2025

Feb 05, 2025

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference - BioSpace

Feb 05, 2025

Feb 05, 2025

Revolutionary Warfarin Alternative Takes Center Stage: Cadrenal CEO to Unveil Latest Tecarfarin Data - StockTitan

Feb 05, 2025

Jan 31, 2025

(CVKD) Investment Report - Stock Traders Daily

Jan 31, 2025

Jan 23, 2025

Cadrenal Therapeutics (NASDAQ:CVKD) Trading 14.3% Higher – Time to Buy? - Defense World

Jan 23, 2025

Jan 21, 2025

Ponte Vedra-based Cadrenal CEO Quang Pham talks biotech, funding - The Business Journals

Jan 21, 2025

Jan 21, 2025

Learn to Evaluate (CVKD) using the Charts - Stock Traders Daily

Jan 21, 2025

Jan 13, 2025

Ponte Vedra biotech firm opens the Nasdaq - The Business Journals

Jan 13, 2025

Jan 10, 2025

(CVKD) Long Term Investment Analysis - Stock Traders Daily

Jan 10, 2025

Jan 09, 2025

Cadrenal Therapeutics CEO to Present Breakthrough Anticoagulant at Lytham Healthcare Summit - StockTitan

Jan 09, 2025

Jan 09, 2025

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Business Wire

Jan 09, 2025

Jan 03, 2025

Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Expands By 5.7% - Defense World

Jan 03, 2025

Dec 31, 2024

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications - Business Wire

Dec 31, 2024

Dec 31, 2024

Cadrenal Therapeutics Advances Tecarfarin Development with FDA Orphan Drug Status and $11.3M Cash Position - StockTitan

Dec 31, 2024

Dec 22, 2024

AT&T (NYSE:T) Price Target Raised to $30.00 - Defense World

Dec 22, 2024

Dec 21, 2024

Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 11.6% – Time to Buy? - Defense World

Dec 21, 2024

Dec 20, 2024

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility - The Eastern Progress Online

Dec 20, 2024

Dec 18, 2024

CVKDCadrenal Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Dec 18, 2024

Dec 18, 2024

Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings - Business Wire

Dec 18, 2024

Dec 09, 2024

(CVKD) Trading Report - Stock Traders Daily

Dec 09, 2024

Nov 23, 2024

What is Zacks Small Cap’s Estimate for CVKD FY2024 Earnings? - Defense World

Nov 23, 2024

Nov 20, 2024

CVKD: Recent Financings Raise $9.8 Million… - MSN

Nov 20, 2024

Nov 19, 2024

Kairos Pharma approved to dual list on Upstream - MSN

Nov 19, 2024

Nov 19, 2024

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook - StockTitan

Nov 19, 2024

Nov 18, 2024

(CVKD) Technical Data - Stock Traders Daily

Nov 18, 2024

Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Cadrenal Therapeuti - GuruFocus.com

Nov 15, 2024

Nov 12, 2024

Cadrenal's Tecarfarin Shows Promise for LVAD Patients in Key Medical Congress Data | CVKD Stock News - StockTitan

Nov 12, 2024

Nov 12, 2024

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS - PR Newswire

Nov 12, 2024

Nov 11, 2024

Cadrenal shares gain; analyst highlights Buy rating and key LVAD trial advancements - Investing.com Canada

Nov 11, 2024

Nov 09, 2024

Cadrenal Therapeutics Provides Third-Quarter Corporate Update - Defense World

Nov 09, 2024

Nov 08, 2024

Cadrenal Therapeutics Advances Tecarfarin Development - TipRanks

Nov 08, 2024

Nov 07, 2024

Cadrenal Therapeutics Raises $9.8M, Advances Unique Anticoagulant Drug Development | CVKD Stock News - StockTitan

Nov 07, 2024

Nov 01, 2024

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds - StockTitan

Nov 01, 2024

Oct 31, 2024

Here's Why We're Watching Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation - Simply Wall St

Oct 31, 2024

Oct 28, 2024

We're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Rate - Yahoo Finance

Oct 28, 2024

Oct 28, 2024

(CVKD) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 28, 2024

Oct 24, 2024

Cadrenal Therapeutics secures $5.1 million in share sale - Investing.com

Oct 24, 2024

Oct 24, 2024

Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin - TipRanks

Oct 24, 2024

Oct 23, 2024

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM - PR Newswire

Oct 23, 2024

Oct 17, 2024

Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Drops By 7.2% - MarketBeat

Oct 17, 2024

Oct 15, 2024

Renaissance Technologies LLC Reduces Stock Position in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) - MarketBeat

Oct 15, 2024

Oct 07, 2024

Long Term Trading Analysis for (CVKD) - Stock Traders Daily

Oct 07, 2024

Oct 03, 2024

Jacksonville stocks rise as market hits record highs - Jacksonville Daily Record

Oct 03, 2024

Sep 30, 2024

Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Rises By 22.8% - MarketBeat

Sep 30, 2024